Call Options

14 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 10, 2024

SELL
$47.98 - $54.4 $9.67 Million - $11 Million
-201,500 Reduced 16.62%
1,011,100 $54.8 Million
Q4 2023

Feb 09, 2024

BUY
$48.48 - $57.85 $4.85 Million - $5.79 Million
100,000 Added 8.99%
1,212,600 $62.2 Million
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $23.2 Million - $26 Million
401,100 Added 56.37%
1,112,600 $64.6 Million
Q2 2023

Aug 15, 2023

BUY
$63.71 - $70.74 $9.06 Million - $10.1 Million
142,200 Added 24.98%
711,500 $45.5 Million
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $26.3 Million - $29.8 Million
-400,400 Reduced 41.29%
569,300 $39.5 Million
Q4 2022

Feb 13, 2023

BUY
$68.48 - $81.09 $102,720 - $121,635
1,500 Added 0.15%
969,700 $69.8 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $9,230 - $5.46 Million
-71,000 Reduced 6.83%
968,200 $68.8 Million
Q2 2022

Aug 12, 2022

BUY
$72.62 - $79.98 $5.03 Million - $5.53 Million
69,200 Added 7.13%
1,039,200 $80 Million
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $14 Million - $16.7 Million
-227,200 Reduced 18.98%
970,000 $70.8 Million
Q1 2021

May 13, 2021

BUY
$59.34 - $66.74 $27.8 Million - $31.3 Million
468,600 Added 64.32%
1,197,200 $75.6 Million
Q4 2020

Feb 09, 2021

SELL
$57.74 - $65.43 $16.8 Million - $19 Million
-290,800 Reduced 28.53%
728,600 $3.75 Million
Q3 2020

Nov 05, 2020

BUY
$57.43 - $63.64 $3.78 Million - $4.19 Million
65,800 Added 6.9%
1,019,400 $3.42 Million
Q2 2020

Aug 13, 2020

BUY
$54.82 - $64.09 $32.6 Million - $38.1 Million
595,000 Added 165.92%
953,600 $3.74 Million
Q1 2020

May 14, 2020

BUY
$46.4 - $67.43 $16.6 Million - $24.2 Million
358,600 New
358,600 $1.19 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $86B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.